PURPOSE: Before developing a survivorship care plan (SCP) that colorectal cancer (CRC) survivors will value, understanding the informational needs of CRC survivors is critical. METHODS: We surveyed survivors treated for nonmetastatic CRC at two hospitals in New York about their needs and preferences for survivorship information. Participants completed treatment 6 to 24 months before the interview and had not received an SCP. We evaluated whether survivors knew their treatment history (10 topics), whether they understood ongoing risks (four topics), and their preferences for receiving 16 topics of survivorship information. RESULTS: One hundred seventy-five survivors completed the survey. Most survivors remembered information about past treatment (98% to 99% for each treatment). Fewer survivors knew their risks of local recurrence, distant recurrence, or developing a new CRC (69%, 77%, and 40%, respectively). Most participants reported receiving information about their cancer history and ongoing oncology visits (77% to 86% across topics). Across all topics, 93% to 99% of those who reported receiving information found the information useful. A minority of survivors reported they received information about symptoms to report to doctors, returning to work, or financial or legal issues (5% to 48% across topics), but those who did found the information useful (89% to 100% across topics). CONCLUSIONS: In the absence of an SCP, CRC survivors still generally understood their cancer history. However, many lacked knowledge of ongoing risks and prevention. Most survivors stated that they found the survivorship information they received useful. SCPs for CRC survivors should focus less on past care and more on helping survivors understand their risks and plan for the future.
PURPOSE: Before developing a survivorship care plan (SCP) that colorectal cancer (CRC) survivors will value, understanding the informational needs of CRC survivors is critical. METHODS: We surveyed survivors treated for nonmetastatic CRC at two hospitals in New York about their needs and preferences for survivorship information. Participants completed treatment 6 to 24 months before the interview and had not received an SCP. We evaluated whether survivors knew their treatment history (10 topics), whether they understood ongoing risks (four topics), and their preferences for receiving 16 topics of survivorship information. RESULTS: One hundred seventy-five survivors completed the survey. Most survivors remembered information about past treatment (98% to 99% for each treatment). Fewer survivors knew their risks of local recurrence, distant recurrence, or developing a new CRC (69%, 77%, and 40%, respectively). Most participants reported receiving information about their cancer history and ongoing oncology visits (77% to 86% across topics). Across all topics, 93% to 99% of those who reported receiving information found the information useful. A minority of survivors reported they received information about symptoms to report to doctors, returning to work, or financial or legal issues (5% to 48% across topics), but those who did found the information useful (89% to 100% across topics). CONCLUSIONS: In the absence of an SCP, CRC survivors still generally understood their cancer history. However, many lacked knowledge of ongoing risks and prevention. Most survivors stated that they found the survivorship information they received useful. SCPs for CRC survivors should focus less on past care and more on helping survivors understand their risks and plan for the future.
Authors: Stephen J Rulyak; Margaret T Mandelson; Teresa A Brentnall; Carolyn M Rutter; Edward H Wagner Journal: Gastrointest Endosc Date: 2004-02 Impact factor: 9.427
Authors: Carol A Rosenberg; Carol Flanagan; Bruce Brockstein; Jennifer C Obel; Leon H Dragon; Douglas E Merkel; Elaine L Wade; Teresa M Law; Janardan D Khandekar; Thomas A Hensing Journal: J Cancer Surviv Date: 2015-07-16 Impact factor: 4.442
Authors: Michael Jefford; Karla Gough; Allison Drosdowsky; Lahiru Russell; Sanchia Aranda; Phyllis Butow; Jo Phipps-Nelson; Jane Young; Mei Krishnasamy; Anna Ugalde; Dorothy King; Andrew Strickland; Michael Franco; Robert Blum; Catherine Johnson; Vinod Ganju; Jeremy Shapiro; Geoffrey Chong; Julie Charlton; Andrew Haydon; Penelope Schofield Journal: Oncologist Date: 2016-06-15
Authors: Lahiru Russell; Karla Gough; Allison Drosdowsky; Penelope Schofield; Sanchia Aranda; Phyllis N Butow; Jennifer A Westwood; Mei Krishnasamy; Jane M Young; Jo Phipps-Nelson; Dorothy King; Michael Jefford Journal: J Cancer Surviv Date: 2015-01-09 Impact factor: 4.442
Authors: Michael Jefford; Jon Emery; Eva Grunfeld; Andrew Martin; Paula Rodger; Alexandra M Murray; Richard De Abreu Lourenco; Alexander Heriot; Jo Phipps-Nelson; Lisa Guccione; Dorothy King; Karolina Lisy; Niall Tebbutt; Adele Burgess; Ian Faragher; Rodney Woods; Penelope Schofield Journal: Trials Date: 2017-10-30 Impact factor: 2.279
Authors: Lisa M Lowenstein; Robert J Volk; Amanda Cuddy; Andrea P Hempstead; Y Nancy You; Katherine Van Loon; Stefanos Millas; Jeffrey A Meyerhardt; Patrick Gavin; George J Chang Journal: BMJ Open Date: 2019-08-15 Impact factor: 2.692
Authors: G Perl; S Nordheimer; S Lando; C Benedict; B Brenner; S Perry; G Shmoisman; O Purim; L Amit; S M Stemmer; I Ben-Aharon Journal: BMC Cancer Date: 2016-08-12 Impact factor: 4.430